Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Monday

Milestone Pharmaceuticals (NASDAQ:MIST) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Milestone Pharmaceuticals to post earnings of ($0.19) per share for the quarter.

Milestone Pharmaceuticals Trading Down 7.5 %

Shares of MIST stock opened at $1.11 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $2.75. The stock has a 50 day simple moving average of $1.33 and a two-hundred day simple moving average of $1.72. The company has a market cap of $59.35 million, a P/E ratio of -1.37 and a beta of 0.86.

Analyst Ratings Changes

Several research analysts have commented on MIST shares. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. Cowen downgraded Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 1st. TD Cowen cut Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 1st. Finally, TD Securities lowered shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Milestone Pharmaceuticals has a consensus rating of “Hold” and an average target price of $17.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.